DOCSLIB.ORG

Precision Medicine in the Management of Type 2 Diabetes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Precision Medicine in the Management of Type 2 Diabetes Review Precision medicine in the management of type 2 diabetes Anna L Gloyn, Daniel J Drucker The study of type 2 diabetes has been driven by advances in human genetics, epigenetics, biomarkers, mechanistic Lancet Diabetes Endocrinol 2018 studies, and large clinical trials, enabling new insights into disease susceptibility, pathophysiology, progression, and Published Online development of complications. Simultaneously, several new drug classes with different mechanisms of action have April 23, 2018 been introduced over the past two decades, accompanied by data about cardiovascular safety and non-glycaemic http://dx.doi.org/10.1016/ S2213-8587(18)30052-4 outcomes. In this Review, we critically examine the progress and integration of this new science into clinical practice, Oxford Centre for Diabetes, and review opportunities for enabling the use of precision medicine in the diagnosis and treatment of type 2 diabetes. Endocrinology and We contrast the success in delivering personalised medicine for monogenic diabetes with the greater challenge of Metabolism, Radcliffe providing a precision medicine approach for type 2 diabetes, highlighting gaps, limitations, and areas requiring Department of Medicine, and further study. Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK Introduction a marked sensitivity to sulfonylureas, a finding that was (Prof A L Gloyn DPhil); NIHR There has been much interest in our increased ability to elegantly substantiated in a randomised controlled trial Oxford Biomedical Research incorporate data from human genetics, along with that provided the first example of personalised medicine Centre, Churchill Hospital, Oxford, UK (Prof A L Gloyn); 3 lifestyle and environmental information, to individualise in diabetes. The precise molecular mechanism for and Department of Medicine, treatment decisions. Although not a novel concept, the sensitivity to this class of oral hypoglycaemic drugs in Lunenfeld-Tanenbaum technological advancements that have driven the omics patients with HNF1A mutations remains elusive but it Research Institute, Mount Sinai revolution have provided the impetus and expectation has been argued that closure of the ATP­sensitive Hospital, University of Toronto, Toronto, ON, Canada that a new dawn in precision medicine is approaching. In potassium (KATP) channel by sulfonylureas bypasses the (D J Drucker MD) this Review, we use the term precision medicine to major sites of β­cell dysfunction, which are upstream of Correspondence to: describe the stratification of patients into groups on the the KATP channel, thus reigniting insulin secretion. Dr Daniel J Drucker, Mount Sinai basis of molecular and genetic biomarkers and clinical Sulfonylureas are also the first­line treatment for indivi­ Hospital, Toronto, ON M5G 1X5, characteristics to optimise therapeutic outcomes. The duals with neonatal diabetes due to activating mutations Canada [email protected] scope of precision medicine has appropriately been in the KCNJ11 and ABCC8 genes, which prevent the KATP broadened to not only include genetics but also channels from closing in response to ATP generated by environmental and lifestyle factors, with recommen­ glycolysis.4–7 Closure of the channel by an ATP­ dations targeting groups rather than individual patients. independent mechanism circumvents the cause of the In this Review, we examine the evidence for precision β­cell dysfunction, restoring insulin secretion in these medicine in diabetes, focusing on its success in individuals and, remarkably, improving their glycaemic monogenic diabetes, the emerging evidence for type 2 control. diabetes, and identifying challenges for enabling Personalised medicine in monogenic diabetes extends improved individualised treatment recommendations in beyond treatment response: for example, individuals with the future. loss­of­function mutations in the GCK gene have stable fasting hyperglycaemia and are unlikely to develop Precision medicine in monogenic versus diabetic complications.8 For neonatal diabetes, non­ polygenic diabetes selective genetic testing now provides information about The past 10 years have seen unprecedented progress in the future development of additional clinical features, our understanding of the genetic basis of diabetes. With disease management, and likelihood of disease remission.9 this progress has come an expectation among the clinical To date, however, genetic discovery efforts for community that our ability to diagnose, characterise, and type 2 diabetes have had limited translational benefits. treat patients with diabetes will be transformed. Given Reconciling the different bench­to­bedside trajectories of the well documented success in rapid translation of gene monogenic versus complex forms of diabetes can be discovery efforts for monogenic varieties of diabetes into achieved by appreciating the differences in the genetic changes in clinical care pathways, this belief is under­ contributions to the development of diabetes, which standable. Up to 3% of cases of diabetes diagnosed in makes the eventual classification of type 2 diabetes into children have a monogenic basis, with the most common multiple discrete subtypes less likely than into monogenic cause being mutations in the transcription factor gene forms of diabetes (figure). As researchers have tried to HNF1A.1 Individuals with rare penetrant mutations in understand how genetics might be used to support HNF1A typically present before age 25 years with non­ precision medicine, several theories have been proposed insulin­dependent diabetes, are slim, and have a strong for complex diseases such as type 2 diabetes and coronary family history of diabetes. Clinical investigation usually artery disease. Two untested models10,11 that have garnered reveals that such individuals are autoantibody negative interest propose that patients with type 2 diabetes or but C­peptide positive. An early case study2 showed that coronary artery disease are likely to have a diverse set of individuals with diabetes due to an HNF1A mutation had overlapping mechanisms for their inability to regulate www.thelancet.com/diabetes-endocrinology Published online April 23, 2018 http://dx.doi.org/10.1016/S2213-8587(18)30052-4 1 Review A B Single gene disorder Complex trait Examples of monogenic subtypes of diabetes GCK HNFA KCNJ PPARG/LMNA Glucose sensing Insulin secretion Channel disorder Ectopic fat Examples of treatment No treatment Low dose High dose Metformin sulfonylurea sulfonylurea Insulin sensitisers Sulfonylureas Incretin therapies Figure: Precision medicine approaches for the treatment of type 2 diabetes (A) Treatment of patients with selected monogenic subtypes of diabetes. (B) Individuals with complex genetic determinants of type 2 diabetes. Monogenic diabetes subtypes have specific treatments whereas complex trait type 2 diabetes is a sliding scale making individualised treatment more difficult. Many subtypes of monogenic diabetes can be treated with specific pharmcological agents, whereas individuals with type 2 diabetes have a heterogeneous phenotype, with different degrees of abnormalities in multiple pathways. their blood glucose or lipid concentrations, respectively, in about 9000 newly diagnosed patients with diabetes, and that these combinations will be difficult to tease the researchers were able to identify five subtypes of apart into discrete subtypes. Both models propose that diabetes based on clinical variables (autoantibodies, age what matters is where an individual is on a series of at diagnosis, BMI, HbA1c, and estimates of β­cell function hypothetical sliding scales of intermediate phenotypes and insulin resistance), which were replicated in for particular pathophysiological processes (eg, β­cell independent cohorts. In support of the presence of mass, insulin sensitivity, and incretin response in different pathophysiological features, the clustering of patients with type 2 diabetes, or LDL cholesterol con­ established genetic associations differed between these centrations in patients with coronary artery disease).10,11 If subtypes. In line with different degrees of shared patho­ we can understand the composition of the pallette or physiology, the risks of complications differed across the blend and where individuals are located on these sliding subtypes. Notably, diabetic retinopathy was identified scales then we can make more tailored treatment choices, earlier in patients with relative insulin deficiency, particularly when identifying patients who are unlikely to whereas patients with insulin­resistant diabetes showed respond to a particular therapy. For example, people with an increased risk of developing diabetic kidney disease.14 diabetes largely due to loss of β­cell mass are unlikely to These findings, if replicated in ethnically diverse respond to drugs that increase insulin secretion. There is populations across a range of age groups, might be of already evidence for this hypothesis from studies potential value for clinical trial enrolment or for early showing the reduced efficacy of glucagon­like peptide­1 treatment stratification, perhaps with drugs such as (GLP­1) receptor agonists in insulin­treated patients with sodium­glucose cotransporter 2 (SGLT2) inhibitors, low C­peptide concentrations and autoantibodies.12 which show potential for modification of renal out­ Encouraging evidence for the clinical utility of genetic comes.15 Future studies will now need to establish risk profiling has emerged from efforts to understand whether
Load more

Recommended publications
  • EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies
    Focusing on Personalised Medicine EXTENDED CARRIER SCREENING Peace of Mind for Planned Pregnancies Extended carrier screening is an important tool for prospective parents to help them determine their risk of having a child affected with a heritable disease. In many cases, parents aren’t aware they are carriers and have no family history due to the rarity of some diseases in the general population. What is covered by the screening? Genomics For Life offers a comprehensive Extended Carrier Screening test, providing prospective parents with the information they require when planning their pregnancy. Extended Carrier Screening has been shown to detect carriers who would not have been considered candidates for traditional risk- based screening. With a simple mouth swab collection, we are able to test for over 419 genes associated with inherited diseases, including Fragile X Syndrome, Cystic Fibrosis and Spinal Muscular Atrophy. The assay has been developed in conjunction with clinical molecular geneticists, and includes genes listed in the NIH Genetic Test Registry. For a list of genes and disorders covered, please see the reverse of this brochure. If your gene of interest is not covered on our Extended Carrier Screening panel, please contact our friendly team to assist you in finding a gene test panel that suits your needs. Why have Extended Carrier Screening? Extended Carrier Screening prior to pregnancy enables couples to learn about their reproductive risk and consider a complete range of reproductive options, including whether or not to become pregnant, whether to use advanced reproductive technologies, such as preimplantation genetic diagnosis, or to use donor gametes.
    [Show full text]
  • ABCB6 Is a Porphyrin Transporter with a Novel Trafficking Signal That Is Conserved in Other ABC Transporters Yu Fukuda University of Tennessee Health Science Center
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 12-2008 ABCB6 Is a Porphyrin Transporter with a Novel Trafficking Signal That Is Conserved in Other ABC Transporters Yu Fukuda University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Chemicals and Drugs Commons, and the Medical Sciences Commons Recommended Citation Fukuda, Yu , "ABCB6 Is a Porphyrin Transporter with a Novel Trafficking Signal That Is Conserved in Other ABC Transporters" (2008). Theses and Dissertations (ETD). Paper 345. http://dx.doi.org/10.21007/etd.cghs.2008.0100. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. ABCB6 Is a Porphyrin Transporter with a Novel Trafficking Signal That Is Conserved in Other ABC Transporters Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Interdisciplinary Program Research Advisor John D. Schuetz, Ph.D. Committee Linda Hendershot, Ph.D. James I. Morgan, Ph.D. Anjaparavanda P. Naren, Ph.D. Jie Zheng, Ph.D. DOI 10.21007/etd.cghs.2008.0100 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/345 ABCB6 IS A PORPHYRIN TRANSPORTER WITH A NOVEL TRAFFICKING SIGNAL THAT
    [Show full text]
  • Transcriptional and Post-Transcriptional Regulation of ATP-Binding Cassette Transporter Expression
    Transcriptional and Post-transcriptional Regulation of ATP-binding Cassette Transporter Expression by Aparna Chhibber DISSERTATION Submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Pharmaceutical Sciences and Pbarmacogenomies in the Copyright 2014 by Aparna Chhibber ii Acknowledgements First and foremost, I would like to thank my advisor, Dr. Deanna Kroetz. More than just a research advisor, Deanna has clearly made it a priority to guide her students to become better scientists, and I am grateful for the countless hours she has spent editing papers, developing presentations, discussing research, and so much more. I would not have made it this far without her support and guidance. My thesis committee has provided valuable advice through the years. Dr. Nadav Ahituv in particular has been a source of support from my first year in the graduate program as my academic advisor, qualifying exam committee chair, and finally thesis committee member. Dr. Kathy Giacomini graciously stepped in as a member of my thesis committee in my 3rd year, and Dr. Steven Brenner provided valuable input as thesis committee member in my 2nd year. My labmates over the past five years have been incredible colleagues and friends. Dr. Svetlana Markova first welcomed me into the lab and taught me numerous laboratory techniques, and has always been willing to act as a sounding board. Michael Martin has been my partner-in-crime in the lab from the beginning, and has made my days in lab fly by. Dr. Yingmei Lui has made the lab run smoothly, and has always been willing to jump in to help me at a moment’s notice.
    [Show full text]
  • The Role of Mitochondrial ATP-Binding Cassette Transporter
    The Role of Mitochondrial ATP-Binding Cassette Transporter ABCB6 in Metabolism and Energy Balance By © 2019 Robert T Tessman Submitted to the graduate degree program in Toxicology and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Committee Chair: Partha Kasturi, PhD Bruno Hagenbuch, PhD Hao Zhu, PhD Tiangang Li, PhD Luciano DiTacchio, PhD Date Defended: April 19th, 2019Title Page ii The dissertation committee for Robert T Tessman certifies that this is the approved version of the following dissertation: The role of Mitochondrial ATP-Binding Cassette Transporter ABCB6 in Metabolism and Energy Balance Committee Chair: Partha Kasturi, PhD Acceptance Page Date Approved: April 19th, 2019 iii Abstract Obesity and the associated health risks represent a world-wide health and financial crisis. Lack of physical activity combined with excessive caloric intake are the root cause of the problem. Despite the increased advocation for healthy lifestyle choices, the trend has yet to reverse and indeed, seems to be on the rise especially among pre- teens and adolescents, a constituent that had not been previously part of the obesity epidemic. Mitochondria are the “fuel-burners” of the body and like other combustion devices, become inefficient in the context of fuel surplus. Moreover, with chronic over-feeding, the physiological mechanisms that regulate energy balance become permanently dysfunctional leading to the progression of pathologies such as Type II diabetes and cardiovascular disease. Medical and scientific evidence confirms that mitochondria are integral to the responses necessary to adapt to over-nutrition. However, success in mitochondria- based therapies has been extremely limited in the context of metabolic diseases.
    [Show full text]
  • The Putative Mitochondrial Protein ABCB6
    Shifting the Paradigm: The Putative Mitochondrial Protein ABCB6 Resides in the Lysosomes of Cells and in the Plasma Membrane of Erythrocytes Katalin Kiss, Anna Brozik, Nora Kucsma, Alexandra Toth, Melinda Gera, Laurence Berry, Alice Vallentin, Henri Vial, Michel Vidal, Gergely Szakacs To cite this version: Katalin Kiss, Anna Brozik, Nora Kucsma, Alexandra Toth, Melinda Gera, et al.. Shifting the Paradigm: The Putative Mitochondrial Protein ABCB6 Resides in the Lysosomes of Cells and in the Plasma Membrane of Erythrocytes. PLoS ONE, Public Library of Science, 2012, 7 (5), pp.e37378. 10.1371/journal.pone.0037378. hal-02309092 HAL Id: hal-02309092 https://hal.archives-ouvertes.fr/hal-02309092 Submitted on 25 May 2021 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution| 4.0 International License Shifting the Paradigm: The Putative Mitochondrial Protein ABCB6 Resides in the Lysosomes of Cells and in the Plasma Membrane of Erythrocytes Katalin Kiss1, Anna Brozik1, Nora Kucsma1, Alexandra Toth1, Melinda Gera1,
    [Show full text]
  • Whole-Exome Sequencing Identifies Novel Mutations in ABC Transporter
    Liu et al. BMC Pregnancy and Childbirth (2021) 21:110 https://doi.org/10.1186/s12884-021-03595-x RESEARCH ARTICLE Open Access Whole-exome sequencing identifies novel mutations in ABC transporter genes associated with intrahepatic cholestasis of pregnancy disease: a case-control study Xianxian Liu1,2†, Hua Lai1,3†, Siming Xin1,3, Zengming Li1, Xiaoming Zeng1,3, Liju Nie1,3, Zhengyi Liang1,3, Meiling Wu1,3, Jiusheng Zheng1,3* and Yang Zou1,2* Abstract Background: Intrahepatic cholestasis of pregnancy (ICP) can cause premature delivery and stillbirth. Previous studies have reported that mutations in ABC transporter genes strongly influence the transport of bile salts. However, to date, their effects are still largely elusive. Methods: A whole-exome sequencing (WES) approach was used to detect novel variants. Rare novel exonic variants (minor allele frequencies: MAF < 1%) were analyzed. Three web-available tools, namely, SIFT, Mutation Taster and FATHMM, were used to predict protein damage. Protein structure modeling and comparisons between reference and modified protein structures were performed by SWISS-MODEL and Chimera 1.14rc, respectively. Results: We detected a total of 2953 mutations in 44 ABC family transporter genes. When the MAF of loci was controlled in all databases at less than 0.01, 320 mutations were reserved for further analysis. Among these mutations, 42 were novel. We classified these loci into four groups (the damaging, probably damaging, possibly damaging, and neutral groups) according to the prediction results, of which 7 novel possible pathogenic mutations were identified that were located in known functional genes, including ABCB4 (Trp708Ter, Gly527Glu and Lys386Glu), ABCB11 (Gln1194Ter, Gln605Pro and Leu589Met) and ABCC2 (Ser1342Tyr), in the damaging group.
    [Show full text]
  • Analysis of Arabidopsis Abcb Auxin Transporter Mutants Reveals a Primary Role in Membrane Exclusion
    ABSTRACT Title of Dissertation: ANALYSIS OF ARABIDOPSIS ABCB AUXIN TRANSPORTER MUTANTS REVEALS A PRIMARY ROLE IN MEMBRANE EXCLUSION Mark Kubo Jenness, Doctor of Philosophy, 2018 Dissertation directed by: Professor Angus S. Murphy, Department of Plant Science and Landscape Architecture Polar transport of the phytohormone auxin regulates multiple of aspects of plant growth and development. A subset of plant ATP-binding cassette subfamily B (ABCB) transporters mediate cellular auxin export. Loss of these transporters results in reduced polar auxin movement and altered plant architecture but no significant defects in embryogenesis or organ formation. Several of lines of evidence suggest that isotropically-localized ABCB transporters mediate auxin exclusion from the plasma membrane and prevention of reuptake after directional PIN-mediated efflux. Examination of the Arabidopsis auxin transporters ABCB1 and ABCB19 indicates a primary role in exclusion from small auxin producing cells in apical regions and prevention of leakage from polar auxin transport streams. Analysis of abcb mutants identifies a contribution from ABCB21 in restricting auxin to within the root vasculature in seedlings. In mature tissues, ABCB6, ABCB21, and ABCB11 make additional contributions to polar auxin transport in inflorescence stems, leaves, and flowers, respectively. The results presented herein reflect an evolutionarily conserved function for ABCB transporters in maintaining polar transport streams and prevention of cellular reuptake via exclusion. ANALYSIS OF ARABIDOPSIS ABCB AUXIN TRANSPORTER MUTANTS REVEALS A PRIMARY ROLE IN MEMBRANE EXCLUSION by Mark Kubo Jenness Dissertation submitted to the Faculty of the Graduate School of the University of Maryland, College Park, in partial fulfillment of the requirements for the degree of Doctor of Philosophy 2018 Advisory Committee: Professor Angus Murphy, Chair Professor David Hawthorne Professor Jianhua Zhu Professor Wendy A.
    [Show full text]
  • Role of Genetic Variation in ABC Transporters in Breast Cancer Prognosis and Therapy Response
    International Journal of Molecular Sciences Article Role of Genetic Variation in ABC Transporters in Breast Cancer Prognosis and Therapy Response Viktor Hlaváˇc 1,2 , Radka Václavíková 1,2, Veronika Brynychová 1,2, Renata Koževnikovová 3, Katerina Kopeˇcková 4, David Vrána 5 , Jiˇrí Gatˇek 6 and Pavel Souˇcek 1,2,* 1 Toxicogenomics Unit, National Institute of Public Health, 100 42 Prague, Czech Republic; [email protected] (V.H.); [email protected] (R.V.); [email protected] (V.B.) 2 Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 323 00 Pilsen, Czech Republic 3 Department of Oncosurgery, Medicon Services, 140 00 Prague, Czech Republic; [email protected] 4 Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, 150 06 Prague, Czech Republic; [email protected] 5 Department of Oncology, Medical School and Teaching Hospital, Palacky University, 779 00 Olomouc, Czech Republic; [email protected] 6 Department of Surgery, EUC Hospital and University of Tomas Bata in Zlin, 760 01 Zlin, Czech Republic; [email protected] * Correspondence: [email protected]; Tel.: +420-267-082-711 Received: 19 November 2020; Accepted: 11 December 2020; Published: 15 December 2020 Abstract: Breast cancer is the most common cancer in women in the world. The role of germline genetic variability in ATP-binding cassette (ABC) transporters in cancer chemoresistance and prognosis still needs to be elucidated. We used next-generation sequencing to assess associations of germline variants in coding and regulatory sequences of all human ABC genes with response of the patients to the neoadjuvant cytotoxic chemotherapy and disease-free survival (n = 105).
    [Show full text]
  • Influence of ABCA1 and ABCA7 on the Lipid Microenvironment of the Plasma Membrane
    I Influence of ABCA1 and ABCA7 on the lipid microenvironment of the plasma membrane Dissertation zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) im Fach Biologie eingereicht an der Mathematisch-Naturwissenschaftlichen Fakultät I der Humboldt-Universität zu Berlin von Dottore Magistrale in Biotecnologie Industriali Anna Pia Plazzo geb. 17.10.1981 in San Giovanni Rotondo, Italien Präsident der Humboldt-Universität zu Berlin Prof. Dr. Dr. h.c. Christoph Markschies Dekan der Mathematisch-Naturwissenschaftlichen Fakultät I Prof. Dr. Lutz-Helmut Schön Gutachter: 1. Prof. Dr. Andreas Herrmann 2. Prof. Dr. Thomas Günther-Pomorski 3. Prof. Dr. Thomas Eitinger Tag der mündlichen Prüfung: 12.06.2009 II Alla mia famiglia III Zusammenfassung Der ABC-Transporter ABCA1 ist unmittelbar in die zelluläre Lipidhomeostasie einbezogen, in dem er die Freisetzung von Cholesterol an plasmatische Rezeptoren, wie ApoA-I, vermittelt. Trotz intensiver Untersuchungen ist dieser molekulare Mechanismus nicht verstanden. Verschiedene Studien deuten daraufhin, dass durch die Aktivität von ABCA1 bedingte Veränderungen in der Lipidphase der äußeren Hälfte der Plasmamembran (PM) wichtig für die Freisetzung des Cholesterols sind. In der vorliegenden Arbeit wird die Lipidumgebung von ABCA1 in der PM lebender Säugetierzellen unter Anwendung der Fluoreszenzlebenszeitmikroskopie von fluoreszierenden Lipidsonden untersucht. Es wurde eine breite Verteilung der Fluoreszenzlebenszeiten der Sonden gefunden, die sensitiv gegenüber Veränderungen der lateralen und transversalen Organisation der Lipide ist. Im Einklang mit Studien an riesengroßen unilamellaren Vesikeln und Plasmamembranvesikeln weisen unsere Ergebnisse die Existenz einer größeren Vielfalt submikroskopischer Lipiddomänen auf. Die FLIM-Untersuchungen an ABCA1 exprimierenden HeLa-Zellen weisen eine die Lipidphase destabilisierende Funktion des Transportes aus. Dieses wurde unterstützt durch die Lipidanalyse von Fraktionen der PM.
    [Show full text]
  • Histological Demonstration of BSEP/ABCB11 Inhibition In
    Baghdasaryan et al. BMC Pediatrics (2020) 20:340 https://doi.org/10.1186/s12887-020-02201-x CASE REPORT Open Access Histological demonstration of BSEP/ABCB11 inhibition in transient neonatal cholestasis: a case report Anna Baghdasaryan1* , Lisa Ofner-Ziegenfuß2, Carolin Lackner3, Peter Fickert4, Bernhard Resch5, Nicholas Mark Morris5 and Andrea Deutschmann1 Abstract Background: Idiopathic or transient neonatal cholestasis (TNC) represents a group of cholestatic disorders with unidentified origin and remains a diagnosis of exclusion. Dysfunction of hepatobiliary transporters mediating excretion of biliary constituents from hepatocytes may play a central role in the pathogenesis of cholestasis. Despite variants of bile salt (BS) export pump (BSEP/ABCB11) have already been described in TNC, the pathogenic role of BSEP dysfunction in TNC remained so far elusive. Case presentation: We report on a newly-identified heterozygous ABCB11 missense variant (c.1345G > A, p.Glu449Lys) which was associated with prolonged cholestasis in a term infant after a complicated neonatal period. Moreover, we show for the first time almost completely abolished BSEP expression on the hepatocellular membrane in TNC. Conclusion: This report demonstrates for the first time a close association between the prolonged cholestasis in infancy and impaired BSEP expression on the hepatocyte canalicular membrane in a heterozygous carrier of newly- identified ABCB11 variant. Keywords: BSEP deficiency, Transient neonatal cholestasis Background neonatal intensive care unit develop TNC, suggesting in- Idiopathic or transient neonatal cholestasis (TNC) repre- volvement of genetic predisposing mechanisms. sents a group of intrahepatic cholestatic disorders in in- Bile salt (BS) excretion from hepatocytes is mediated fancy with poorly understood pathogenesis. It is by BS-specific canalicular transporter the bile salt export characterized by onset of cholestasis in the first week of pump (BSEP/ABCB11).
    [Show full text]
  • ATP-Binding-Cassette Transporters in Biliary Efflux and Drug-Induced Liver Injury
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 172 ATP-Binding-Cassette Transporters in Biliary Efflux and Drug-Induced Liver Injury JENNY M. PEDERSEN ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6192 ISBN 978-91-554-8702-7 UPPSALA urn:nbn:se:uu:diva-204200 2013 Dissertation presented at Uppsala University to be publicly examined in B21, BMC, Husargatan 3, Uppsala, Sweden, Friday, September 6, 2013 at 09:15 for the degree of Doctor of Philosophy (Faculty of Pharmacy). The examination will be conducted in English. Abstract Pedersen, J. M. 2013. ATP-Binding-Cassette Transporters in Biliary Efflux and Drug-Induced Liver Injury. Acta Universitatis Upsaliensis. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 172. 67 pp. Uppsala. ISBN 978-91-554-8702-7. Membrane transport proteins are known to influence the absorption, distribution, metabolism, excretion and toxicity (ADMET) of drugs. At the onset of this thesis work, only a few structure-activity models, in general describing P-glycoprotein (Pgp/ABCB1) interactions, were developed using small datasets with little structural diversity. In this thesis, drug-transport protein interactions were explored using large, diverse datasets representing the chemical space of orally administered registered drugs. Focus was set on the ATP-binding cassette (ABC) transport proteins expressed in the canalicular membrane of human hepatocytes.The inhibition of the ABC transport proteins multidrug-resistance associated protein 2 (MRP2/ ABCC2) and bile salt export pump (BSEP/ABCB11) was experimentally investigated using membrane vesicles from cells overexpressing the investigated proteins and sandwich cultured human hepatocytes (SCHH). Several previously unknown inhibitors were identified for both of the proteins and predictive in silico models were developed.
    [Show full text]
  • Current Treatment Options for Cystic Fibrosis-Related Liver Disease
    International Journal of Molecular Sciences Review Current Treatment Options for Cystic Fibrosis-Related Liver Disease Katharina Staufer Department of Visceral Surgery and Medicine, Inselspital, University Hospital Bern, 3010 Bern, Switzerland; [email protected]; Tel.: +41-31-63-2-74-88 Received: 13 September 2020; Accepted: 11 November 2020; Published: 14 November 2020 Abstract: Cystic Fibrosis-related liver disease (CFLD) has become a leading cause of morbidity and mortality in patients with Cystic Fibrosis (CF), and affects children and adults. The understanding of the pathogenesis of CFLD is key in order to develop efficacious treatments. However, it remains complex, and has not been clarified to the last. The search for a drug might be additionally complicated due to the diverse clinical picture and lack of a unified definition of CFLD. Although ursodeoxycholic acid has been used for decades, its efficacy in CFLD is controversial, and the potential of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators and targeted gene therapy in CFLD needs to be defined in the near future. This review focuses on the current knowledge on treatment strategies for CFLD based on pathomechanistic viewpoints. Keywords: cystic fibrosis-related liver disease; CFTR modulators; ursodeoxycholic acid; liver transplantation 1. Introduction Cystic Fibrosis-related liver disease (CFLD) represents one of multiple optional organ manifestations of Cystic Fibrosis (CF), the most frequent fatal autosomal recessive disorder in Caucasians [1,2]. CF is a monogenic disease resulting from mutations within the cystic fibrosis transmembrane conductance regulator (CFTR) on chromosome 7 currently comprising >2000 different mutations [3]. CFTR encodes for a protein that is found i.a.
    [Show full text]